Aaron Dane

2.6k total citations · 1 hit paper
52 papers, 1.9k citations indexed

About

Aaron Dane is a scholar working on Surgery, Pharmacology and Epidemiology. According to data from OpenAlex, Aaron Dane has authored 52 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Surgery, 17 papers in Pharmacology and 16 papers in Epidemiology. Recurrent topics in Aaron Dane's work include Lipoproteins and Cardiovascular Health (13 papers), Antibiotics Pharmacokinetics and Efficacy (12 papers) and Antibiotic Resistance in Bacteria (10 papers). Aaron Dane is often cited by papers focused on Lipoproteins and Cardiovascular Health (13 papers), Antibiotics Pharmacokinetics and Efficacy (12 papers) and Antibiotic Resistance in Bacteria (10 papers). Aaron Dane collaborates with scholars based in United Kingdom, United States and Germany. Aaron Dane's co-authors include Mike J. Warwick, Paul Martin, Dennis W. Schneck, Ali Raza, Eva M. Lenz, Steve Hill, P. J. Phillips, Mireille Cantarini, John Rex and John Kemp and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Aaron Dane

52 papers receiving 1.9k citations

Hit Papers

Cefepime–Taniborbactam in Complicated Urinary Tract Infec... 2024 2026 2025 2024 20 40 60
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cefepime–Taniborbactam in Complicated Urinary Tract Infection
    2024 67 citations Aaron Dane et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aaron Dane United Kingdom 26 614 416 407 396 363 52 1.9k
John Lettieri United States 25 204 0.3× 270 0.6× 377 0.9× 790 2.0× 381 1.0× 77 1.9k
Lee B. Barradell 18 253 0.4× 155 0.4× 257 0.6× 323 0.8× 155 0.4× 24 1.3k
Martin Bergstrand Sweden 17 228 0.4× 142 0.3× 340 0.8× 487 1.2× 425 1.2× 38 2.5k
Flora T. Musuamba Belgium 22 255 0.4× 68 0.2× 324 0.8× 292 0.7× 192 0.5× 48 1.8k
Howard Greenberg United States 26 355 0.6× 96 0.2× 294 0.7× 549 1.4× 218 0.6× 63 2.1k
Ulrika S. H. Simonsson Sweden 29 289 0.5× 155 0.4× 544 1.3× 619 1.6× 354 1.0× 114 2.6k
Dong‐Seok Yim South Korea 21 121 0.2× 90 0.2× 202 0.5× 262 0.7× 213 0.6× 112 1.3k
Christopher Banfield United States 30 96 0.2× 110 0.3× 301 0.7× 426 1.1× 515 1.4× 88 2.8k
Sophie L. Stocker Australia 28 476 0.8× 41 0.1× 271 0.7× 621 1.6× 547 1.5× 115 2.6k
Indravadan H. Patel United States 27 175 0.3× 175 0.4× 334 0.8× 917 2.3× 224 0.6× 75 2.4k

Countries citing papers authored by Aaron Dane

Since Specialization
Citations

This map shows the geographic impact of Aaron Dane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron Dane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron Dane more than expected).

Fields of papers citing papers by Aaron Dane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron Dane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron Dane. The network helps show where Aaron Dane may publish in the future.

Co-authorship network of co-authors of Aaron Dane

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron Dane. A scholar is included among the top collaborators of Aaron Dane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron Dane. Aaron Dane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
He, Aiwu Ruth, Do‐Youn Oh, Teresa Macarulla, et al.. (2024). TOURMALINE: A phase 3b study of durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS4188–TPS4188. 1 indexed citations
2.
Vehreschild, Maria J. G. T., et al.. (2023). An obituary on DAV-132—authors’ viewpoint on the current limits of pivotal trials in clinical microbiome research. Journal of Antimicrobial Chemotherapy. 78(6). 1551–1553. 2 indexed citations
3.
4.
Johnson, Adam, Laura McEntee, Nicola Farrington, et al.. (2020). Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 64(6). 27 indexed citations
5.
McEntee, Laura, Adam Johnson, Nicola Farrington, et al.. (2019). Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. Antimicrobial Agents and Chemotherapy. 63(8). 39 indexed citations
6.
Hope, William, Silvia Cicconi, Timothy Felton, et al.. (2019). Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study. Antimicrobial Agents and Chemotherapy. 63(4). 19 indexed citations
7.
Talbot, George H., Anita Das, Stephanie S. Cush, et al.. (2018). Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. The Journal of Infectious Diseases. 219(10). 1536–1544. 53 indexed citations
8.
Rex, John, George H. Talbot, Mark Goldberger, et al.. (2017). Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance. Clinical Infectious Diseases. 65(1). 141–146. 47 indexed citations
9.
McDonnell, Anthony, John Rex, Herman Goossens, et al.. (2016). Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks. Clinical Infectious Diseases. 63(suppl 2). S57–S59. 24 indexed citations
10.
Rex, John, Barry I. Eisenstein, Jeff Alder, et al.. (2013). A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. The Lancet Infectious Diseases. 13(3). 269–275. 92 indexed citations
11.
Southworth, Harry & Aaron Dane. (2008). Models for the analysis of C‐reactive protein in statin trials. Pharmaceutical Statistics. 8(2). 87–97. 1 indexed citations
12.
Martin, Paul, et al.. (2003). Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. British Journal of Clinical Pharmacology. 55(1). 94–99. 77 indexed citations
13.
Martin, Paul, et al.. (2003). The effect of erythromycin on the pharmacokinetics of rosuvastatin. European Journal of Clinical Pharmacology. 59(1). 51–56. 77 indexed citations
14.
Martin, Paul, Mike J. Warwick, Aaron Dane, et al.. (2003). Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clinical Therapeutics. 25(11). 2822–2835. 233 indexed citations
15.
16.
Martin, Paul, Mike J. Warwick, Aaron Dane, & Mireille Cantarini. (2003). A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clinical Therapeutics. 25(8). 2215–2224. 48 indexed citations
17.
Cooper, Kevin D., Paul Martin, Aaron Dane, et al.. (2002). The effect of fluconazole on the pharmacokinetics of rosuvastatin. European Journal of Clinical Pharmacology. 58(8). 527–531. 92 indexed citations
18.
Martín, Paul, et al.. (2002). No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor. The Journal of Clinical Pharmacology. 42(10). 1116–1121. 64 indexed citations
19.
Martin, Paul, John Kemp, Aaron Dane, Mike J. Warwick, & Dennis W. Schneck. (2002). No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers. The Journal of Clinical Pharmacology. 42(12). 1352–1357. 42 indexed citations
20.
Swaisland, Helen, et al.. (2001). Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers. Clinical Pharmacokinetics. 40(4). 297–306. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John Lettieri Breakdown of academic impact, for papers by Lee B. Barradell Breakdown of academic impact, for papers by Martin Bergstrand Breakdown of academic impact, for papers by Flora T. Musuamba Breakdown of academic impact, for papers by Howard Greenberg Breakdown of academic impact, for papers by Ulrika S. H. Simonsson Breakdown of academic impact, for papers by Dong‐Seok Yim Breakdown of academic impact, for papers by Christopher Banfield Breakdown of academic impact, for papers by Sophie L. Stocker Breakdown of academic impact, for papers by Indravadan H. Patel
Rankless by CCL
2026